



HAL
open science

Pentadecaibins I–V: 15-Residue Peptaibols Produced by a Marine-Derived Trichoderma sp. of the Harzianum Clade

Anne-Isaline van Bohemen, Nicolas Ruiz, Aurore Zalouk-Vergnoux, Aurore Michaud, Thibaut Robiou Du Pont, Irina Druzhinina, Lea Atanasova, Soizic Prado, Bernard Bodo, Laurence Meslet-Cladiere, et al.

► To cite this version:

Anne-Isaline van Bohemen, Nicolas Ruiz, Aurore Zalouk-Vergnoux, Aurore Michaud, Thibaut Robiou Du Pont, et al.. Pentadecaibins I–V: 15-Residue Peptaibols Produced by a Marine-Derived Trichoderma sp. of the Harzianum Clade. *Journal of Natural Products*, 2021, 84 (4), pp.1271-1282. <10.1021/acs.jnatprod.0c01355>. <hal-03148991>

HAL Id: hal-03148991

<https://hal.science/hal-03148991v1>

Submitted on 3 Mar 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Pentadecaibins I–V: 15-Residue Peptaibols Produced by a Marine-Derived *Trichoderma* sp. of the *Harzianum* Clade

Journal:	<i>Journal of Natural Products</i>
Manuscript ID	np-2020-01355y.R1
Manuscript Type:	Full Paper
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>van Bohemen, Anne-Isaline; Université de Nantes, Faculty of Pharmacy Ruiz, Nicolas; Université de Nantes, Faculty of Pharmacy Zalouk-Vergnoux, Aurore ; Université de Nantes, Faculty of Pharmacy Michaud, Aurore; Université de Nantes, Faculty of Pharmacy Robiou du Pont, Thibaut; Université de Nantes, Faculty of Pharmacy Druzhinina, Irina; Nanjing Agricultural University, Fungal Genomics Laboratory Atanasova, Lea; University of Natural Resources and Life Sciences Vienna, BOKU Institute of Food Technology PRADO, Soizic ; Museum National d'Histoire Naturelle, Unité Molécules de Communication et Adaptation des Micro-organismes Bodo, Bernard; Museum National d'Histoire Naturelle, Unité Molécules de Communication et Adaptation des Micro-organismes Meslet-Cladière, Laurence; Université de Bretagne Occidentale, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne Cochereau, Bastien; Université de Nantes, Faculty of Pharmacy Bastide, Franck; Université d'Angers, IRHS - INRAE Maslard, Corentin; Université d'Angers, IRHS - INRAE Marchi, Muriel; INRA Angers, IRHS Guillemette, Thomas; Université d'Angers, IRHS - INRAE Pouchus, Yves François; Université de Nantes, Faculté de Pharmacie</p>

SCHOLARONE™
Manuscripts

1 **Pentadecaibins I–V: 15-Residue Peptaibols Produced by a**
2 **Marine-Derived *Trichoderma* sp. of the *Harzianum* Clade**

3 Anne-Isaline van Bohemen,[†] Nicolas Ruiz,^{*,†} Aurore Zalouk-Vergnoux,[†] Aurore Michaud,[†]
4 Thibaut Robiou du Pont,[†] Irina Druzhinina,^{‡,§} Lea Atanasova,[⊥] Soizic Prado,^{||} Bernard Bodo,^{||}
5 Laurence Meslet-Cladiere[∇], Bastien Cochereau,^{∇,†} Franck Bastide,[#] Corentin Maslard,[#] Muriel
6 Marchi,[#] Thomas Guillemette,[#] and Yves François Pouchus[†]

7 [†] Université de Nantes, MMS - EA2160, 44000 Nantes, France

8 [‡] Institute of Chemical, Environmental and Bioscience Engineering, TU Wien, Vienna, Austria

9 [§] Fungal Genomics Laboratory (FungiG), Nanjing Agricultural University, Nanjing, China

10 [⊥] Department of Food Science and Technology, University of Natural Resources and Life Sciences – BOKU,
11 Vienna, Austria

12 ^{||} Muséum National d'Histoire Naturelle, Unité Molécules de Communication et Adaptation des Micro-organismes,
13 UMR 7245, CP 54, 57 rue Cuvier, 75005 Paris, France

14 [∇] Université de Brest, Laboratoire Universitaire de Biodiversité et Ecologie Microbienne, 29280 Plouzané, France

15 [#] IRHS-UMR1345, Université d'Angers, INRAE, Institut Agro, SFR 4207 QuaSaV, 49071, Beaucouzé, France

1
2
3 1 ABSTRACT: In the course of investigations on peptaibol chemodiversity from marine-derived
4
5 2 *Trichoderma* spp., five new 15-residue peptaibols named pentadecaibins I–V (1–5) were isolated
6
7 3 from the solid culture of the strain *Trichoderma* sp. MMS1255 belonging to the *T. harzianum*
8
9 4 species complex. Phylogenetic analyses allowed precise positioning of the strain close to
10
11 5 *T. lentiforme* lineage inside the *Harzianum* clade. Peptaibol sequences were elucidated on the basis
12
13 6 of their MS/MS fragmentation and extensive 2D-NMR experiments. Amino acid configurations
14
15 7 were determined by Marfey's analyses. The pentadecaibins are based on the sequences Ac-Aib1-
16
17 8 Gly2-Ala3-Leu4-Aib/Iva5-Gln6-Aib/Iva7-Val/Leu8-Aib9-Ala10-Aib11-Aib12-Aib13-Gln14-
18
19 9 Pheo15. Characteristic of the pentadecaibin sequences is the lack of the Aib-Pro motif commonly
20
21 10 present in peptaibols produced by *Trichoderma* spp. Genome sequencing of *Trichoderma* sp.
22
23 11 MMS1255 allowed the detection of a 15-module NRPS-encoding gene closely associated with
24
25 12 pentadecaibin biosynthesis. Pentadecaibins were assessed for their potential antiproliferative and
26
27 13 antimicrobial activities.
28
29
30
31
32
33
34
35
36 14
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 Numerous fungi belonging to the genus *Trichoderma* are known to produce bioactive linear
4
5 2 nonribosomal peptides (NRP) named peptaibols. Peptaibols are characterized by molecular masses
6
7 3 ranging from 500 to 2 000 Da containing 5-20 amino-acid (AA) residues, an *N*-acetyl terminus and
8
9 4 a *C*-terminal AA reduced into the corresponding amino-alcohol.¹⁻⁴ Peptaibol biosynthesis by non
10
11 5 ribosomal peptide synthetases (NRPS)⁵⁻⁷ allows incorporation of non-proteinogenic AA into the
12
13 6 chain such as α -aminoisobutyric acid (Aib) or isovaline (Iva).² In *Trichoderma* spp., peptaibols are
14
15 7 produced as complex microheterogeneous mixtures and can be classified into five main families
16
17 8 (11-, 14-, 18-, 19- and 20-residue peptaibols) according to their AA chain length. Peptaibols
18
19 9 represent the most important subgroup of the peptaibiotics group and numerous sequences have
20
21 10 already been published and listed in the *Comprehensive Peptaibiotics Database*.^{8,9}
22
23
24
25
26

27 11 Peptaibols have been studied for their potential biological activities particularly as alternative
28
29 12 sources for antibiotic research or as new therapeutic agents.^{10,11} Indeed, they have been shown to
30
31 13 exhibit a wide range of biological activities including antibacterial activity against Gram-positive
32
33 14 bacteria¹²⁻¹⁵ and dormant mycobacteria,^{16,17} antifungal activity,^{14,18,19} antiviral activity -
34
35 15 particularly against infection caused by the tobacco mosaic virus,²⁰⁻²² and antiparasitic activity
36
37 16 against amoebae (*Dictyostelium* sp.)²³ and protozoa (*Plasmodium falciparum*).²⁴ They have been
38
39 17 also studied for their activities against fungal plant pathogens.²⁵⁻²⁸ Peptaibols are known to act by
40
41 18 forming pores or voltage-dependent ion channels in cell membranes increasing membrane
42
43 19 permeability.^{23,29}
44
45
46
47

48 20 In a continuation of our investigations into peptaibol chemodiversity of French marine-derived
49
50 21 *Trichoderma*,³⁰⁻³³ we focused in this study on the peptaibol production of the strain *Trichoderma*
51
52 22 sp. MMS1255. Phylogenetic analysis was performed to determine the precise taxonomic position
53
54
55
56
57
58
59
60

1 of the peptaibol-producing strain within the *Trichoderma* genus and more specifically in the
2 *T. harzianum* species complex. Peptaibols isolated contained 15 AA and were characterized by the
3 lack of the widespread Aib-Pro motif. Their sequences were determined by MS analysis and their
4 complete structures were established by NMR spectroscopy. Marfey analysis and circular
5 dichroism were used for the determination of the AA configurations. The genome sequencing of
6 the peptaibol-producing strain revealed the presence of a new gene encoding a 15 module-NRPS.
7 The organization of modules and domains in this gene has never been described before and may
8 be involved in the biosynthesis of the isolated peptaibols. Cytotoxicity and antimicrobial activities
9 were shown for these new compounds.

10

1 RESULTS AND DISCUSSION

2 **Morphological and Phylogenetic Analyses of *Trichoderma* sp. MMS1255.** The Dextrose
3 Casein Agar (DCA) culture of strain MMS1255 was observed as successive concentric greenish to
4 whitish zones on the agar surface plate. Microscopically, typically highly branched conidiophores
5 were observed producing clustered phialides arising near 90° with respect to the others members
6 (Figure S1). The taxonomic identification was performed by DNA Barcoding (Table S1, Figure
7 S2). Preliminary molecular identification based on the internal transcribed spacer regions of the
8 nuclear ribosomal RNA gene cluster (ITS1 and ITS2) led to the *Trichoderma harzianum* species
9 complex. However, ITS is not sufficiently polymorphic to distinguish species in the *T. harzianum*
10 complex,³⁴ thus we used the translation elongation factor 1- α (*tefl*) and RNA polymerase II subunit
11 2 (*rpb2*) gene markers. This analysis localized the strain *Trichoderma* sp. MMS1255 among the
12 *Trichoderma Harzianum* Clade (Figure S6).³⁵ For a deeper identification inside this infrageneric
13 group, we performed a combined analysis of the marker genes *tefl* and calmodulin (*cal*). This
14 resulted in the identification of the strain MMS1255 close to the *T. lentiforme* lineage and to two
15 isolates previously described as *T. harzianum* JBNZ24 and JBNZ111 (Figure 1).³⁶ Considering the
16 Genealogical Concordance Phylogenetic Species Recognition (GCPSR) concept,³⁷ further
17 phenotyping characterizations are needed to clarify *Trichoderma* sp. MMS1255, *T. harzianum*
18 JBNZ24 and JBNZ111 phylogenetic localization within or outside the borders of *T. lentiforme*.





Figure 1. Phylogram of the best maximum likelihood tree (log likelihood: -4619.24) of *tefl* and *cal*, which includes only species in the *T. harzianum* complex. Values at nodes represent ML bootstrap (MLBP)/MP bootstrap (MPBP). The tree is drawn to scale, with branch lengths measured in the number of substitutions per site. The analysis involved 76 nucleotide sequences. There were a total of 734 positions in the final dataset. Evolutionary analyses were conducted in MEGA7.³⁸

1 **Isolation and Structure Elucidation of Pentadecaibins (1–5).** A peptaibol-enriched fraction
 2 extracted from a solid culture (DCA) of *Trichoderma* sp. MMS1255 was analyzed by MS and
 3 revealed the presence of an unusual MS profile with $[M + Na]^+$ ions ranging from m/z 1466 to 1521
 4 (Figure S3). Whereas ions ranging from m/z 1466 to m/z 1493 were supposed to correspond to 14-
 5 residue peptaibols produced by *Trichoderma* strains,^{5,26,39,40} ions m/z 1493 and m/z 1521 did not
 6 match any known peptaibols. Herein, we report the discovery, structure elucidation and biological
 7 activities of five 15-residue peptaibols (1-5) isolated from the marine-derived strain *Trichoderma*
 8 sp. MMS1255.

9 Chart 1


Ac - Aib¹ - Gly² - Ala³ - Leu⁴ - **Aib/D-Iva**⁵ - Gln⁶ - **Aib/D-Iva**⁷ - **Val/Leu**⁸ - Aib⁹ - Ala¹⁰ - Aib¹¹ - Aib¹² - Aib¹³ - Gln¹⁴ - Pheol¹⁵



	R ₁	R ₂	R ₃
1	Me (Aib ⁵)	Me (Aib ⁷)	<i>iso</i> -propyl (Val ⁸)
2	Me (Aib ⁵)	Me (Aib ⁷)	<i>iso</i> -butyl (Leu ⁸)
3	Me (Aib ⁵)	Et (D-Iva ⁷)	<i>iso</i> -propyl (Val ⁸)
4	Me (Aib ⁵)	Et (D-Iva ⁷)	<i>iso</i> -butyl (Leu ⁸)
5	Et (D-Iva ⁵)	Et (D-Iva ⁷)	<i>iso</i> -propyl (Val ⁸)

11 Compound **1** was obtained as a white powder. The molecular formula was determined to be
 12 C₆₈H₁₁₃N₁₇O₁₈ on the basis of HRESIMS (m/z 750.9132 $[M + 2Na]^{2+}$). The amino acid sequence
 13 of **1** was determined on the basis of ESIMS² analyses by identifying fragment ions of the series a_n,
 14 b_n, y_{nP} generated in positive ionization (P refers to positive-ion mode) and y_{nN} generated in negative

1 ionization (N for negative-ion mode) (Figure 2, Table S2). Fragmentation of the sodium adduct
2 $[M + Na]^+$ produced a series of fragment ions a_5/b_5 to a_{14}/b_{14} providing successive losses of Gln⁶,
3 Aib⁷, Vxx⁸, Aib⁹, Ala¹⁰, Aib¹¹, Aib¹², Aib¹³, Gln¹⁴ and the C-terminal Pheol¹⁵ (phenylalaninol; Vxx
4 = Val or Iva). In order to complete the sequence, ESI-MS² fragmentation of the deprotonated
5 molecule $[M - H]^-$ yielded diagnostic fragment ions y_{4N} to y_{14N} . Hence, the N-terminal part of the
6 sequence was assigned as Ac-Aib¹-Gly²-Ala³-Lxx⁴-Aib⁵-Gln⁶-Aib⁷-Vxx⁸-Aib⁹-Ala¹⁰-Aib¹¹ (Lxx =
7 Leu or Ile). Fragment ions y_{7P} to y_{14P} assigned in positive mode supported the N-terminal sequence
8 deduced from the y_{nN} ions series. Based on the above mass spectrometry analysis, the sequence of
9 **1** was proposed to be Ac-Aib¹-Gly²-Ala³-Lxx⁴-Aib⁵-Gln⁶-Aib⁷-Vxx⁸-Aib⁹-Ala¹⁰-Aib¹¹-Aib¹²-
10 Aib¹³-Gln¹⁴-Pheol¹⁵.



1 **Figure 2.** Positive and negative ESI-MS² fragmentation of pentadecaibin I (1).

2

The sequence determined from mass spectral fragmentations was thus verified by 1D and 2D-NMR correlations allowing in addition the assignment of the isomeric residues Val/Iva and Leu/Ile (Figure 3, Table 1).




Figure 3. NMR key correlations of pentadecaibin I (**1**) (COSY/TOCSY, HMBC and NOESY).

The ^1H NMR spectrum of compound **1** exhibited in the range 6.7-9 ppm, 17 exchangeable signals characteristic of amide protons among which 11 singlets corresponding to seven Aib residues, two side-chain NH_2 protons of the two Gln, one broad singlet characterising one Gly, five doublets (for Ala, Leu, two Gln and Val) and two multiplets (for Ala and Pheol). In addition, the aromatic protons of the mono-substituted phenyl ring of the Pheol were characterized by multiplets at δ_{H} 7.13, 7.18 and 7.27. Between δ_{H} 1.48 and 1.37 ppm were depicted 14 methyl singlets assigned to seven Aib residues.

^1H - ^1H correlations from COSY and TOCSY spectra allowed to define seven spin systems corresponding to Gly, two Ala, Leu, Val and two Gln as represented in bold in Figure 3. An additional moiety was pointed out by ^1H - ^1H correlations between a hydroxy group at δ_{H} 4.53, the methylene group at δ_{H} 3.37 (δ_{C} 63.2) and the methine at δ_{H} 3.89 (δ_{C} 52.4), which itself was linked to the NH at δ_{H} 7.13 and the methylene at δ_{H} 2.89/2.57 (δ_{C} 36.7). ^1H - ^{13}C HMBC correlations allowed this methylene carbon to be linked to the protons of the phenyl ring, resulting in the characterization of a Pheol residue (Table 1). The ϵ -amide protons of the two Gln were assigned from their HMBC correlations with the corresponding γ -carbon and their *syn* or *anti*-disposition

1
2
3 1 from their NOE correlations with the respective γ -protons of the lateral chain (Figure S15). The
4
5 2 carbonyl at δ_C 171.0 was assigned to the *N*-terminal acetyl because its HMBC correlation with the
6
7 3 methyl at δ_H 1.93 and the NH of an Aib at δ_H 8.74, thus assigned to Aib¹. The carbonyl of this Aib¹
8
9 4 at δ_C 176.1 was correlated not only to the NH of Aib¹, but also to the α,α' -protons of Gly². The
10
11 5 CO of Gly² at δ_C 171.8 gave cross-peaks with these α,α' -protons and the NH at δ_H 8.00 (d, $J =$
12
13 6 6.3) assigned to Ala³. Continuing this series of NH_{*i*+1} to CO_{*i*} correlations thus observed from Ac-
14
15 7 Aib¹ to Pheol¹⁵, the following completed sequence of **1** was finally confirmed as Ac-Aib¹-Gly²-
16
17 8 Ala³-Leu⁴-Aib⁵-Gln⁶-Aib⁷-Val⁸-Aib⁹-Ala¹⁰-Aib¹¹-Aib¹²-Aib¹³-Gln¹⁴-Pheol¹⁵ and was named
18
19 9 pentadecaibin I (**1**). The sequences of the other isolated peptaibols were identified and
20
21 10 characterized in the same way.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Table 1. ¹H and ¹³C NMR of Pentadecaibin I (1) (¹H 600 MHz, ¹³C 150 MHz DMSO-*d*₆)**

Pos.	δ _c , type	δ _H , mult. (<i>J</i> in Hz)	Pos.	δ _c , type	δ _H , mult. (<i>J</i> in Hz)	Pos.	δ _c , type	δ _H , mult. (<i>J</i> in Hz)
Ac-Aib ¹			Gln ⁶			Aib ¹¹		
C=O	176.1, C	-	C=O	173.1, C	-	C=O	175.2, C	-
N-H	-	8.74, s	N-H	-	7.83, d (2.6)	N-H	-	7.87, s
α C	55.6, C	-	α CH	56.7, CH	3.74, m	α C	55.5, C	-
β CH ₃	(*), CH ₃	(°) s	β CH ₂	26, CH ₂	2.02, m	β CH ₃	(*), CH ₃	(°) s
β' CH ₃	(*), CH ₃	(°) s		-	1.89, m	β' CH ₃	(*), CH ₃	(°) s
COCH ₃	171.0, C	-	γ CH ₂	31.1, CH ₂	2.22, m			
COCH ₃	23.1, CH ₃	1.93, s		-	2.09, m			
			δ C=O	173.1, C	-			
			εNH _{2 anti}	-	7.18, s			
			εNH _{2 syn}	-	6.73, s			
Gly ²			Aib ⁷			Aib ¹²		
C=O	171.8, C	-	C=O	176.2, C	-	C=O	175.5, C	-
N-H	-	9.06, brs	N-H	-	8.54, s	N-H	-	7.50, s
α CH ₂	43.8, CH ₂	3.83, m (pro S)	α C	57.7, C	-	α C	56.0, C	-
	-	3.59, dd (16.1, 4.6) (pro R)	β CH ₃	(*), CH ₃	(°) s	β CH ₃	(*), CH ₃	(°) s
			β' CH ₃	(*), CH ₃	(°) s	β' CH ₃	(*), CH ₃	(°) s
Ala ³			Val ⁸			Aib ¹³		
C=O	175.4, C	-	C=O	172.7, C	-	C=O	174.5, C	-
N-H	-	8.00, d (6.3)	N-H	-	7.80, d (5.0)	N-H	-	7.97, s
α CH	51.1, CH	4.04, dq (6.3, 7.5)	α CH	63.7, CH	3.37, m	α C	55.8, C	-
β CH ₃	16.1, CH ₃	1.39, d (7.5)	β CH	28.8, CH	2.08, m	β CH ₃	(*), CH ₃	(°) s
			γ CH ₃	18.8, CH ₃	0.98, d (6.4)	β' CH ₃	(*), CH ₃	(°) s
			γ' CH ₃	21.2, CH ₃	0.86, d (6.5)			
Leu ⁴			Aib ⁹			Gln ¹⁴		
C=O	173.7, C	-	C=O	175.5, C	-	C=O	171.2, C	-
N-H	-	7.88, d (8.3)	N-H	-	8.00, s	N-H	-	7.48, d (7.2)
α CH	54.3, CH	4.01, m	α C	55.3, C	-	α CH	54.3, CH	3.84, m
β CH ₂	38.5, CH ₂	1.79, m	β CH ₃	(*), CH ₃	(°) s	β CH ₂	26.8, CH ₂	1.88, m
	-	1.55, m	β' CH ₃	(*), CH ₃	(°) s		-	1.80, m
γ CH	24.3, CH	1.53, m				γ CH ₂	31.8, CH ₂	2.16, m
δ CH ₃	22.4, CH ₃	0.83, d (6.5)					-	1.94, m
δ' CH ₃	21.6, CH ₃	0.87, d (6.5)				δ C=O	173.5, C	-
						εNH _{2 anti}	-	6.99, s
						εNH _{2 syn}	-	6.62, s
Aib ⁵			Ala ¹⁰			Pheol ¹⁵		
C=O	176.2, C	-	C=O	174.4, C	-	NH	-	7.13, m
N-H	-	8.40, s	N-H	-	7.98, m	α CH	52.4, CH	3.89, m
α C	55.5, C	-	α CH	52.2, C	3.85, m	β CH ₂	36.7, CH ₂	2.89, dd (13.4, 4.3)
β CH ₃	(*), CH ₃	(°) s	β CH ₃	16.3, CH ₃	1.38, d (7.5)		-	2.57, dd (13.4, 9.2)
β' CH ₃	(*), CH ₃	(°) s				β CH ₂ OH	63.2, CH ₂	3.37, m
							-	3.37, m
						OH	-	4.53, dd (6.1/6.1)
						C-1	139.3, C	-
						C-2,6	129.3, CH	7.27, m (8.2)
						C-3,5	127.8, CH	7.18, m (8.2, 8.2)
						C-4	125.7, CH	7.12, m (8.2, 8.2)

β/β' CH₃ Aib¹, Aib⁵, Aib⁷, Aib⁹, Aib¹¹, Aib¹², Aib¹³.¹³C (*) 26.9, 26.5, 26.1, 26.0, 25.9, 25.8, 25.8, 23.1, 22.8, 22.7, 22.6, 22.5, 22.4, 21.6, may be interchanged.¹H (°) 1.48, 1.46, 1.46, 1.45, 1.45, 1.43, 1.43, 1.42, 1.39, 1.39, 1.38, 1.38, 1.37, 1.37, may be interchanged.

2

1
2
3 1 Compound **2** was obtained as a white powder. The molecular formula was determined to be
4
5 2 $C_{69}H_{115}N_{17}O_{18}$ on the basis of HRESIMS (m/z 757.9172 $[M + 2Na]^{2+}$) indicating the presence of
6
7 3 an additional methylene group between **1** and **2**. This was confirmed by positive and negative mass
8
9 4 fragmentations (Figures S4-S5, Table S2), suggesting the presence of Ile/Leu in position 8 instead
10
11 5 of Val⁸ for **1**. Detailed analyses of 1D and 2D NMR spectroscopic data were consistent with mass
12
13 6 fragmentation analyses and both residues were identified as leucine from COSY and TOCSY data
14
15 7 (Table S3). HMBC correlations confirmed the second Leu residue in position 8. Indeed, 1H - ^{13}C
16
17 8 correlations were observed between the CO group of the Aib⁷ at δ_C 176.3 was correlated to the NH
18
19 9 at δ_H 7.89 of the Leu⁸ and the CO group of this Leu at δ_C 174.0 was correlated to the methine H α
20
21 10 at δ_H 3.90 (δ_C 54.8) and to the NH at δ_H 8.03 of the Aib⁹ (Figure S27). Therefore, the structure of
22
23 11 compound **2** was established as Ac-Aib¹-Gly²-Ala³-Leu⁴-Aib⁵-Gln⁶-Aib⁷-Leu⁸-Aib⁹-Ala¹⁰-Aib¹¹-
24
25 12 Aib¹²-Aib¹³-Gln¹⁴-Pheol¹⁵ and named pentadecaibin II.

26
27
28
29
30
31 13 Compound **3** was obtained as a white powder and exhibited the same molecular formula
32
33 14 ($C_{69}H_{115}N_{17}O_{18}$) as compound **2**. On the basis of mass fragmentation analyses, compound **3** only
34
35 15 differed from **1** by the presence of a Val/Iva instead of an Aib in position 7 (Figures S6-S7, Table
36
37 16 S2). Mass spectrometry sequencing was confirmed by NMR investigations (Table S4) and the
38
39 17 TOCSY spectrum showed characteristic signals of one Iva and one Val isomeric residues. The CO
40
41 18 group of Gln⁶ at δ_C 173.1 was correlated to the NH of Iva⁷ at δ_H 7.76 and the CO of Iva⁷ at δ_C 176.6
42
43 19 to the NH of Val⁸ at δ_H 7.74 (Figure S36). Thus Aib⁷ in compound **1** was changed into Iva⁷ in **3**.
44
45 20 Compound **3** was identified as Ac-Aib¹-Gly²-Ala³-Leu⁴-Aib⁵-Gln⁶-Iva⁷-Val⁸-Aib⁹-Ala¹⁰-Aib¹¹-
46
47 21 Aib¹²-Aib¹³-Gln¹⁴-Pheol¹⁵ and consequently named pentadecaibin III.

48
49
50
51
52
53 22 Compound **4** was obtained as a white powder. On the basis of HRESIMS studies, the molecular
54
55 23 formula $C_{70}H_{117}N_{17}O_{18}$ was deduced from the Na⁺-adduct ion $[M + 2Na]^{2+}$ at m/z 764.9263. Mass

1 fragmentation analyses (Figures S8-S9) demonstrated that peptide **4** only differs from **3** by the
2 replacement of the Val residue by a Ile/Leu in position 8 (Table S2). Detailed NMR analyses were
3 consistent with mass fragmentation sequencing and revealed that compound **4** only differed from
4 **3** by the presence of two Leu residues instead of one, the presence of an Iva and the absence of Val
5 (Table S5). The CO of Gln⁶ at δ_C 173.2 was correlated to the NH of the Iva⁷ at δ_H 7.78, the CO of
6 which at δ_C 176.8 was correlated to the NH at δ_H 7.85 of the second Leu, which was thus located
7 at position 8 (Figure S45). Therefore, compound **4** was determined as Ac-Aib¹-Gly²-Ala³-Leu⁴-
8 Aib⁵-Gln⁶-Iva⁷-Leu⁸-Aib⁹-Ala¹⁰-Aib¹¹-Aib¹²-Aib¹³-Gln¹⁴-Pheol¹⁵ and named pentadecaibin IV.

9 Compound **5** was obtained as a white powder. HRESIMS analyses of the $[M + 2Na]^{2+}$ at
10 m/z 764.9180 confirmed that compound **5** exhibits the same molecular formula (C₇₀H₁₁₇N₁₇O₁₈) as
11 compound **4**. Based on mass fragmentation sequencing, three Val or Iva residues were assigned in
12 position 5, 7 and 8 (Figures S10-S11, Table S2). NMR investigations confirmed the mass
13 fragmentation and revealed that **5** was characterised by the presence of two Iva and one Val (Table
14 S6, Figure S54). The CO of Leu⁴ at δ_C 173.5 was correlated to the NH at δ_H 8.10 of one of the Iva
15 (Iva⁵). The CO of this Iva at δ_C 176.6 gave a cross-peak in the HMBC spectrum with the NH of
16 Gln⁶ at δ_H 7.80. As the CO of Gln⁶ at δ_C 173.1 was correlated to the NH at δ_H 7.75 of the second
17 Iva (Iva⁷) and the CO of which at δ_C 176.6 was correlated to the NH at δ_H 7.80 of a Val (Val⁸),
18 compound **5** only differed from compound **4** by the replacement of an Aib by an Iva in position 5.
19 Therefore, compound **5** was determined as Ac-Aib¹-Gly²-Ala³-Leu⁴-Iva⁵-Gln⁶-Iva⁷-Val⁸-Aib⁹-
20 Ala¹⁰-Aib¹¹-Aib¹²-Aib¹³-Gln¹⁴-Pheol¹⁵ and named pentadecaibin V.

1
2
3 1 The solution conformation of pentadecaibins in DMSO- d_6 was tentatively examined by NMR,
4
5 2 based on the observed $^3J_{\text{NH},\alpha\text{H}}$ coupling constants and the inter-residue NOE connectivities. The
6
7 3 $^3J_{\text{NH},\alpha\text{H}}$ coupling constants values mainly lower than 7 Hz agreed with a helical structure. The inter-
8
9 4 residue NOE patterns observed for the five pentadecaibins (**1–5**) on their NOESY spectra were
10
11 5 similar, and strong NOE correlations $d_{\text{NN}(i, i+1)}$ and $d_{\alpha\text{N}(i, i+1)}$ were observed, in agreement with the
12
13 6 proposed sequences (Figure 3, Figures S15, S23, S27, S32, S36, S41, S45, S50 and S54). A helical
14
15 7 structure was also obvious from the series of NOESY correlations between contiguous residues
16
17 8 such as strong $d_{\text{NN}(i, i+1)}$, $d_{\text{NN}(i, i+2)}$ and $d_{\text{NN}(i, i+3)}$. The prevalence of a helix stabilised by 4→1 intra-
18
19 9 molecular hydrogen bonds (3₁₀-helix type) over an α -helix which is stabilised by 5→1 intra-
20
21 10 molecular hydrogen bonds arose from the absence of $d_{\text{NN}(i, i+4)}$ and the stronger peaks of $d_{\text{NN}(i, i+2)}$
22
23 11 as compared to $d_{\text{NN}(i, i+3)}$. As similar conformational results were observed for all the five peptaibols,
24
25 12 it was concluded that the substitutions Aib → Iva (positions 5 and 7) and Val → Leu (position 8)
26
27 13 which were responsible for the microheterogeneity of the pentadecaibins were without significant
28
29 14 influence on their secondary structure.
30
31
32
33
34
35

36 15 In addition, on the basis of ECD spectra analyses (Figures S19, S28, S37, S46 and S55), the
37
38 16 occurrence of two negative maxima at 210 and 225 nm and a positive maximum near 200 nm
39
40 17 confirmed the right-handed helical conformation of the pentadecaibins.⁴¹ In this case, for Iva
41
42 18 residues of pentadecaibins III (**3**), IV (**4**) and V (**5**), the large $\Delta\delta_{\text{H}}$ values of ^1H chemical shift
43
44 19 differences between the diastereotopic β -methylene protons (> 0.28 ppm) and the chemical shifts
45
46 20 of γ -methyl protons and β -methylene carbons confirmed the presence of D-configured Iva (Table
47
48 21 2).^{42,43}
49
50
51
52
53
54
55
56
57
58
59
60

Table 2: ^1H and ^{13}C NMR Parameters of Iva Residues in Pentadecaibins III (3), IV (4) and V (5)

NMR parameter	III (3)	IV (4)	V (5)	
	Iva ⁷	Iva ⁷	Iva ⁵	Iva ⁷
$\Delta\delta_{\beta\text{Hb}-\beta\text{Ha}}$	0.66	0.66	0.66	0.52
$\delta_{\text{H}} \gamma\text{-CH}_3$	0.76	0.76	0.76	0.75
$\delta_{\text{C}} \beta\text{-CH}_2$	25.0	24.9	25.0	25.0


Moreover, the absolute configurations of the constituent chiral AA of pentadecaibins I–V (1–5) were determined after acid hydrolysis and subsequent derivatization of the amino acids with Marfey's reagent (L-FDAA)⁴⁴ (Figures S56-S60). Comparison of the L-DAA derivatives of 1–5 with appropriate L- and D- standard AA L-DAA derivatives by reversed-phase LC indicated the presence of L-configured AA for Ala, Val, Leu, Glu (resulting from Gln hydrolysis during Marfey's analysis) and Pheol. Marfey's analyses confirmed the presence of D-configured Iva for compounds 3–5. Consequently, all chiral AA present in pentadecaibins I–V possess the L-configuration except for the Iva residues (D-configuration).

This is the first report of the description of 15-residue peptaibols within the genus *Trichoderma*. These peptaibols are characterized by the lack of the highly conserved Aib-Pro motif which is generally characteristic for peptaibols produced by *Trichoderma* spp. Ampullosporins, chalciporins and tylopeptins, 15-residue peptaibols produced by *Sepedonium* species, are also characterized by the absence of the Aib-Pro motif.⁴⁵⁻⁴⁹ However, these peptaibols exhibit sequence patterns which remain different from pentadecaibins.

Interestingly, no 18-residue peptaibols could be detected in *Trichoderma* sp. MMS1255 strain extracts, whereas *Trichoderma* species belonging to the *T. harzianum* complex are known to produce these peptaibol series.^{5,7} Comparison of new 15- and already known 18-residue patterns produced by various *T. harzianum* strains showed a complete sequence similarity with an absence

1 of a 3 AA sequence (Aib¹²-Pro¹³-Leu¹⁴) (Figure S61). *Trichoderma* sp. MMS1255 genome
 2 sequencing was performed in order to identify the putative NRPS gene encoding the
 3 pentadecaibins.

4 **Genome Sequencing and NRPS Gene Analysis.** The genome was sequenced with the PacBio
 5 technology. We obtained 228 contigs and the genome assembly size was estimated at 38.7 Mbp
 6 which is coherent with the size of the other fungi within the *Trichoderma harzianum* complex.⁵⁰
 7 All sequences were submitted to the AntiSMASH software pipeline.⁵¹ Interestingly, only one
 8 NRPS gene encoding 15-module protein was identified in the genome, estimated to 53.5 kbp
 9 (Figure 4).



10
 11 **Figure 4.** Module organization of the putative NRPS gene encoding the pentadecaibins I–V (1–5). Modules are
 12 indicated by numbers I–XV.

13 The presence of ketoacyl synthase and acyltransferase domain genes before the first module gene
 14 was consistent with the typical *N*-terminal acetylation of peptaibols. The latest domain in the gene
 15 corresponds to a thioesterase domain or reductase domain. This domain catalyzes the reduction of
 16 the acyl thioester into its primary alcohol *via* the aldehyde intermediate,⁵² which is in agreement
 17 with the typical *C*-terminal amino-alcohol of peptaibols. This NRPS-encoding gene analysis was
 18 completed by the prediction of incorporated AA based on the 10 AA signature sequences in the

1 adenylation domains of NRPS modules based on both NRPS/PKS Substrate predictor and by
 2 NRSPredictor2 SVM (Table 7).^{53,54}

3 **Table 3. Prediction of Incorporated AA in Pentadecaibins Based on the Signature Sequences**
 4 **in 15-module NRPS Adenylation Domains**

Amino acid position in pentadecaibins	Signature sequence in NRPS module ^a	Amino acids predicted by NRPS/PKS substrate predictor/NRSPredictor2 SVM (<i>Small clusters prediction</i>) ^b	Amino acids detected in pentadecaibins
0	PKS-AT	Methylmalonyl-CoA	Ac
1	DLGYLAGVFK	Iva /Val,Leu,Ile,Abu,Iva	Aib
2	DLGiiCaVmK	Gly,Ala,Val,Leu,Ile,Abu,Iva/ <i>NP</i>	Gly
3	DVGfVAGVLK	Ala /Gly,Ala	Ala
4	DMGFLGGVaK	Val /Val,Leu,Ile,Abu,Iva	Leu
5	DLGivCGVyK	NP /Val,Leu,Ile,Abu,Iva	Aib/Iva
6	DGGMVGGNYK	Gln /Glu,Gln	Gln
7	DAawIVGVvK	Val,Leu,Ile,Abu,Iva / Val,Leu,Ile,Abu,Iva	Aib/Iva
8	DAFILGgViK	Ala /Val,Leu,Ile,Abu,Iva	Val/Leu
9	DLGYLAGCFK	Iva /Val,Leu,Ile,Abu,Iva	Aib
10	DVGyVAAVYK	Ser/ <i>Ser</i>	Ala
11	DLMYfagVAK	Gly,Ala,Val,Leu,Ile,Abu,Iva/ <i>NP</i>	Aib
12	DLGFLAGVFK	Iva /Val,Leu,Ile,Abu,Iva	Aib
13	DLGILAGLFK	Iva /Val,Leu,Ile,Abu,Iva	Aib
14	DGGMVGGNYK	Gln /Glu,Gln	Gln
15	DgFVIAGicK	NP /Pheol,Trpol	Pheol

^a Shown in the single letter amino acid code. ^b Shown in the three letter amino acid code. NP: No prediction.

5 All signatures in the adenylation domains were consistent with the AA sequences of
 6 pentadecaibins I-V. Based on these results, it can be assumed that pentadecaibins are synthesized
 7 by a 15-module NRPS. This is the first detection of a 15-module peptaibol synthetase gene within
 8 the *Trichoderma* spp. Contrary to other investigated *Trichoderma* strains within the *T. harzianum*
 9 complex, MMS1255 is the only one producing 15-residue peptaibols associated with a 15-module
 10 peptaibol synthetase.

Biological Activities of Pentadecaibins. Biological activities of pentadecaibins I-V (**1–5**) were assessed against cancer cells (KB), Gram-positive (*Staphylococcus aureus*) and negative (*Escherichia coli*) bacteria and human-pathogenic yeast (*Candida albicans*) (Table 4).

Table 4. Biological Activities of Pentadecaibins I-V (1–5)

Compound	Cytotoxicity – IC ₅₀ (μ M)	Antimicrobial activity – MIC (μ g/mL)		
	KB cells	<i>S. aureus</i>	<i>E. coli</i>	<i>C. albicans</i>
1	2.4 \pm 0.1	25 \pm 0	> 100	> 100
2	4.3 \pm 1.1	> 100	> 100	> 100
3	0.8 \pm 0.5	25 \pm 0	> 100	> 100
4	0.8 \pm 0.2	> 100	> 100	> 100
5	0.7 \pm 0.2	25 \pm 0	> 100	> 100
Alm F50/5 ^a	9 \pm 1	n.t. (12.5) ^b	n.t.	n.t.

n.t. not tested.
^a Synthetic alamethicin F50/5⁵⁵; ^b value from ⁵⁶

The Cytotoxic activities of the pentadecaibins were consistent with previous reports of cell growth inhibitory activity of 11- and 20-residue peptaibols from a marine-derived *T. longibrachiatum* strain.^{30,32} Pentadecaibins III-V (**3 – 5**) incorporating a D-Iva⁷ residue instead of Aib⁷ exhibited higher growth inhibitory activity against KB cells than pentadecaibins I–II (**1–2**). Interestingly, similar observations were obtained with trichodermites A–E assessed on SW620 human colorectal carcinoma cells.⁵⁷ Pentadecaibins did not exhibit noticeable growth inhibition against Gram-negative *E. coli* or yeast *C. albicans*. However, moderate antibacterial activity against *S. aureus* was observed for pentadecaibins I (**1**), III (**3**) and V (**5**) with MIC values of 25 μ g/mL, being in agreement with previous observations in the literature for antimicrobial activity.^{30,56}

In conclusion, in this study we have identified a new series of 15-residue peptaibols named pentadecaibins I–IV (**1–5**). They are produced by a marine-derived strain belonging to the *Harzianum* Clade. The phylogenetic position of *Trichoderma* sp. MMS1255 within the

1
2
3 1 *Trichoderma* genus was studied using sequence alignment of combined genes of representatives
4
5 2 *Trichoderma* strains. No precise identification can be proposed, but the phylogenetic analysis
6
7 3 clearly demonstrates the relation of *Trichoderma* sp. MMS1255 to the *T. lentiforme* lineage. The
8
9 4 pentadecaibins discovered differ between them by AA exchange in positions 5 (Aib/Iva), 7
10
11 5 (Aib/Iva) and 8 (Val/Leu). They are all characterized by the lack of the Aib-Pro motif widespread
12
13 6 in peptaibols produced by *Trichoderma* spp. Genome sequencing allowed the identification for the
14
15 7 first time within *Trichoderma* spp. of a 15-module peptaibol synthetase encoding gene closely
16
17 8 related to pentadecaibin biosynthesis, according to the prediction of the incorporated AA. The
18
19 9 pentadecaibins exhibit moderate cytotoxicity on KB cells and antibacterial activity against
20
21
22 10 *S. aureus*.
23
24
25
26
27 11
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 EXPERIMENTAL SECTION

2
3
4
5
6 **General Experimental Procedures.** The specific rotation was measured with a Perkin Elmer
7
8 model 341 polarimeter at 589 nm. UV spectra were obtained from a Shimadzu 1605 UV/visible
9
10 spectrophotometer, at room temperature over a wavelength range of 200–400 (peptaibols 0.1 mM,
11
12 MeOH). ECD experiments were carried out using a Jasco J-810 CD spectropolarimeter. Spectra
13
14 were recorded at room temperature over a wavelength range of 195–260 nm using a 0.2 cm path
15
16 length cuvette (peptaibols 0.1 mM, MeOH). Measurements were performed using a step scan
17
18 scanning mode with data acquisition interval of 0.1 nm, bandwidth of 2 nm and accumulation of 5.
19
20 ECD sample spectra are shown after subtracting the baseline, smoothing and data normalization.
21
22 IR spectra were recorded on a Shimadzu IR Affinity FTIR spectrometer fitted with an ATR
23
24 MiRacle 10. One- and two-dimensional NMR spectra were performed on a Bruker Avance III HD
25
26 600 MHz spectrometer operating at 600.193 MHz and using a triple resonance TCI cryoprobe,
27
28 equipped with shielded gradients z. NMR spectra were recorded in DMSO-*d*₆ solution and were
29
30 processed using the Bruker TOPSPIN 3.2 software. Chemical shifts are expressed in δ (ppm) and
31
32 are referenced to the residual non-deuterated solvent signals (for DMSO-*d*₆ δ_{H} 2.49 and δ_{C} 39.5).
33
34 For the HMBC experiments the delay ($1/2J$) was 70 ms and for the NOESY experiments the mixing
35
36 time was 500 ms. Mass analyses were carried out using a LCQ™ electrospray ionization ion-trap
37
38 mass spectrometer instrument (ESI-IT/MS, Thermo Fischer Scientific) in positive and negative
39
40 mode with capillary temperature of 160°C, capillary voltage of 3.44 V (positive mode) or – 9.81 V
41
42 (negative mode), spray voltage of 4.51 kV, and sheath gas (N₂) flow rate of 19.50 AU. Compounds
43
44 were infused as methanolic solutions (0.5 $\mu\text{g/mL}$) directly into the ESI probe with a 500- μL
45
46 micrometrically automated syringe (Hamilton) at a flow rate of 3 $\mu\text{L}/\text{min}$. All spectra were acquired
47
48 and analyzed by LCQ Xcalibur software (Thermo Fischer Scientific). Total current ion mass
49
50
51
52
53
54
55
56
57
58
59
60

1 spectra (Fullscan mode) were acquired in the range m/z 150 to 2000. Charge state and isotopic
2 distribution were analyzed by a narrow-scan range mode (Zoomscan mode). MS fragmentation
3 was performed by positive and negative ionizations under the same experimental conditions
4 described above for regular MS analysis *via* infusion of methanolic solutions (0.5 $\mu\text{g/mL}$). The
5 sodium adduct ions $[\text{M} + \text{Na}]^+$ and the deprotonated molecules $[\text{M} - \text{H}]^-$ were selected as precursor
6 ions for MS^2 . Peptaibols were sequenced by assignation of the diagnostic fragment ions of the
7 series a_n / b_n and y_{nP} produced in positive-ion mode and y_{nN} produced in negative-ion mode.
8 HRESIMS analyses were conducted using an electrospray ionization ion-trap time-of-flight
9 multistage mass spectrometer (IT-TOFMS, Shimadzu). Organic solvents used for extraction and
10 purification of compounds were purchased from Carlo Erba SDS and distilled prior to use. Water
11 was purified to HPLC-grade quality with a Millipore-QRG ultrapure water system (Millipore). MS
12 analyses were performed using LCMS-grade MeOH (Biosolve). Semi-preparative HPLC
13 purifications and AA Marfey's analysis were carried out on Agilent 1200 HPLC instrument
14 connected to corresponding quaternary pump, fraction collector, DAD detector and Chemstation
15 software. All *D*- and *L*- amino acids, Gly and Aib were purchased from Sigma-Aldrich, except *D*-
16 and *L*-Iva, purchased from Thermo Fisher Scientific. Acetonitrile (CH_3CN) and trifluoroacetic
17 acid (TFA) used for AA Marfey's analysis were purchased from Carlo Erba and Sigma-Adrich,
18 respectively.

19 **Isolation, Fungal Strain Identification and Phylogenetic Analysis.** The fungal strain was
20 isolated from marine sediment collected in a shellfish-farming area from the estuary of the river
21 Loire at Port-du-Bec, France. The isolated strain is deposited in the laboratory fungal collection
22 (MMS-Marine Fungal Collection, University of Nantes) under the reference number MMS1255 as
23 well as in the TU Wien Collection of Industrially Important Microorganisms under the reference

1
2
3 1 TUCIM 5509. Strain MMS1255 was identified as belonging to the genus *Trichoderma* on the basis
4
5 2 of macroscopic and microscopic morphological features (Figure S1). The identification was
6
7 3 completed at the molecular level by amplification and sequencing of internal transcribed spacers
8
9 4 (ITS) and DNA partial sequences of the fourth large intron of translation elongation factor 1- α
10
11 5 (*tefl*); RNA polymerase II subunit 2 (*rpb2*) and calmodulin (*cal*). Sequences were deposited in
12
13 6 GenBank under accession numbers JQ653081.1, KU758964.1, MN450663.1 and MN428075.1,
14
15 7 respectively. Briefly, mycelium for DNA extraction was grown on potato dextrose agar (PDA) and
16
17 8 harvested after seven days. Genomic DNA was extracted according to the microwave mini-prep
18
19 9 procedure described by Goodwin and Lee (1993)⁵⁸ using 100 μ L lysis buffer (50 mM Tris-HCl pH
20
21 10 7.5, 50 mM EDTA, 3% SDS, 1% 2-mercaptoethanol). The final DNA pellet was supplemented
22
23 11 into 100 μ L TE buffer (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) and stored at -20° C until used.
24
25 12 Gene sequences were obtained by polymerase chain reaction (PCR) amplification (GoTaq® G2
26
27 13 Hot Start Polymerase, Promega Corporation) and sequenced using Eurofins Genomics facility.
28
29 14 DNA partial sequences of *cal*, ITS, *rpb2* and *tefl* were amplified using the following primers:
30
31 15 CAL-228F/CAL-737R,⁵⁹ ITS1/ITS4,⁶⁰ fRPB2-5f/fRPB2-7cr⁶¹ and EF1-728f⁵⁹/TEF1LLERev,⁶²
32
33 16 respectively. ITS sequence (JQ653081) allowed to assign MMS1255 strain to *Trichoderma* genus.
34
35 17 A first phylogenetic analysis aiming to affiliate MMS1255 strain to the *Trichoderma* subclades
36
37 18 defined by Jaklitsch and Voglmayr³⁵ was performed using 112 *Trichoderma* spp. combined
38
39 19 sequences of *tefl* and *rpb2* (Table S1). For the *Trichoderma* subclade affiliation tree,
40
41 20 *Protocrea farinosa* sequences were used as outgroup taxa. A second analysis was performed to
42
43 21 determine MMS1255 strain lineages inside the *Trichoderma Harzianum* clade or to the
44
45 22 *T. harzianum* complex defined by Jaklitsch and Voglmayr³⁵ and Chaverri *et al.*,³⁴ respectively.
46
47 23 According to Chaverri *et al.*,³⁴ *T. catoptron* is one of the more distant species from the
48
49
50
51
52
53
54
55
56
57
58
59
60

1 *T. harzianum* complex, thus the *T. catoptron* strain GJS 02-76 sequences were used to root
2 phylogenetic trees. For the *Trichoderma* sp. MMS1255 lineage affiliation to the *T. harzianum*
3 complex, the combined sequences *tefl* and *cal* gene of 76 representative strains were used (Table
4 S1). As described by Jaklitsch and Voglmayr,³⁵ all alignments were produced with the server
5 version of MAFFT (www.ebi.ac.uk/Tools/mafft), with a gap open penalty of 1.0 and a gap
6 extension penalty in the range of 0.05 to 0.1, with a tree building number = 100 and maxiterate =
7 100. The resulting alignments were checked and refined using BioEdit version v. 7.0.5.3.⁶³
8 Maximum likelihood (ML) analysis was performed with MEGA 7.0.26. The general time-
9 reversible model (GTR)⁶⁴ with gamma-distributed substitution rates, additionally assuming a
10 proportion of invariant sites (GTR+I+G) was selected according to the Akaike information
11 criterion (AIC). Initial tree(s) for the heuristic search were obtained automatically by applying
12 Neighbor-Join and BioNJ algorithms to a matrix of pairwise distances estimated using the
13 Maximum Composite Likelihood (MCL) approach, and then selecting the topology with superior
14 log likelihood value. Maximum likelihood bootstrap proportions (MLBP) were computed with
15 1000 replicates. Maximum parsimony (MP) trees were obtained by MEGA 7.0.26 using 1000
16 replicates of heuristic search with random addition of sequences and tree bisection–reconnection
17 (TBR) as the branch-swapping algorithm. All characters were weighted equally. Maximum
18 parsimony bootstrap proportions (MPBP) were calculated from 1000 replicates, each with 10
19 replicates of random addition of taxa. Trees were visualized with MEGA 7.0.26 with MLBP and
20 MPBP above 50% as shown at the nodes.

21 **Analytical Cultivation and Peptaibol Profiling by ESI-IT-MS.** For peptaibol chemical
22 profiling, *Trichoderma* sp. MMS1255 was inoculated onto a Petri dish (10-cm diameter) containing
23 20 mL of marine DCA medium (dextrose 40 g/L, enzymatic digest of casein 10 g/L, agar 15 g/L,

1 Difco, VWR, synthetic sea salt 36 g/L, Reef Crystals, Aquarium Systems). Culture was incubated
2 for 7 days at 27 °C. After incubation, culture was harvested and mycelia and conidia were scraped
3 from the agar surface. The harvested biomass was extracted by CH₂Cl₂/MeOH 1:2 then 2:1 (v/v,
4 30 mL each) for 30 min at room temperature. The combined extracts were filtered, washed with
5 distilled H₂O (10 mL) and evaporated to dryness to provide an organic extract. The extract was
6 fractionated by vacuum liquid chromatography (VLC) on Chromabond adsorbant (OH) 2 Diol (10
7 × 50 mm, 60 Å, 45 µm, Macherey-Nagel) with CH₂Cl₂/EtOH mixtures (98:2 to 85:15, v/v). The
8 peptaibol-enriched fraction eluting with CH₂Cl₂/EtOH 90:10 (v/v) was subjected to ESI-MS
9 analysis in infusion mode.

10 **Preparative Cultivation, Extraction and Purification of Compounds 1-5.** Strain MMS1255
11 was inoculated onto 35 Petri dishes (20-cm diameter) containing 125 mL of marine DCA medium.
12 Cultures were incubated in natural light for 11 days at 27 °C prior to harvesting for biomass
13 extraction, as previously mentioned (see above). After incubation, the harvested biomass was
14 extracted by CH₂Cl₂/MeOH 1:2 then 2:1 (v/v, 1200 mL each) for 2 h at room temperature. The
15 combined extracts were filtered, washed with distilled H₂O (600 mL) and evaporated to dryness to
16 provide an extract (2.8 g). The extract was partitioned in aliquots of 276 mg and fractionated by
17 repetitive VLC, with CH₂Cl₂/EtOH mixtures (98:2, 95:5, 92:8, 90:10 and 85:15, v/v). Peptide-
18 containing fractions (CH₂Cl₂/EtOH 95:5 to 85:15, v/v) were combined to obtain the fraction 2 (940
19 mg) and subjected to a liquid chromatography on an open silica gel column (Chromagel, 200 × 20
20 mm, 60 Å, 35-70 µm, SDS), with CH₂Cl₂/MeOH mixtures (100:0 to 80:20, v/v). Fifteen-residue
21 peptaibols were mainly eluted in the 2-9 and 2-10 CH₂Cl₂/MeOH mixtures (85:15, v/v).
22 Chromatographic separation of the fraction 2-10 (433 mg) by repetitive reversed-phase preparative
23 HPLC (Luna RP18 column, 250 × 10 mm, 100 Å, 5 µm, Phenomenex) yielded five compounds

(1–5) eluting respectively in sub-fractions 2-10-4 to 2-10-8. Mobile phase (MeOH/H₂O 85:15, v/v) was delivered at a constant flow rate of 5 mL/min. Volumes of 900 μL of 10 mg/mL peptaibol solution resuspended in mobile phase were injected. Detection was performed at 230 nm. All data were acquired by HP ChemStation for LC.

Pentadecaibin I (1): white powder, $[\alpha]^{20}_D - 21$ (*c* 0.2, MeOH); UV (MeOH) λ_{\max} (log ϵ) 204 nm (3.46) nm; IR ν_{\max} 3304, 2929, 1645, 1531, 1454, 1384, 1363, 1294, 1220, 1176, 1043 cm⁻¹; ¹H and ¹³C NMR Data, Table 1; ESIMS *m/z* 750.9 [M + 2Na]²⁺, *m/z* 1478.8 [M + Na]⁺. HRESIMS *m/z* 750.9132 [M + 2Na]²⁺ (calcd for ½ C₆₈H₁₁₃N₁₇O₁₈Na₂, 750.9117, Δ 2.0 ppm).

Pentadecaibin II (2): white powder, $[\alpha]^{20}_D - 17.3$ (*c* 0.34, MeOH); UV (MeOH) λ_{\max} (log ϵ) 204 nm (3.45) nm; IR ν_{\max} 3304, 2930, 1649, 1533, 1452, 1384, 1360, 1298, 1225, 1188, 1043 cm⁻¹; ¹H and ¹³C-NMR Data, Table S3; ESIMS *m/z* 757.9 [M + 2Na]²⁺, *m/z* 1492.8 [M + Na]⁺. HRESIMS *m/z* 757.9172 [M + 2Na]²⁺ (calcd for ½ C₆₉H₁₁₅N₁₇O₁₈Na₂, 757.9195, Δ 3.03 ppm).

Pentadecaibin III (3): white powder, $[\alpha]^{20}_D - 15.1$ (*c* 1.0, MeOH); UV (MeOH) λ_{\max} (log ϵ) 204 nm (3.42) nm; IR ν_{\max} 3304, 2935, 1649, 1531, 1456, 1384, 1363, 1290, 1219, 1174, 1043 cm⁻¹; ¹H and ¹³C NMR Data, Table S4; ESIMS *m/z* 757.9 [M + 2Na]²⁺, *m/z* 1492.8 [M + Na]⁺. HRESIMS *m/z* 757.9174 [M + 2Na]²⁺ (calcd for ½ C₆₉H₁₁₅N₁₇O₁₈Na₂, 757.9195, Δ 2.77 ppm).

Pentadecaibin IV (4): white powder, $[\alpha]^{20}_D - 17.9$ (*c* 1.0, MeOH); UV (MeOH) λ_{\max} (log ϵ) 204 nm (3.42) nm; IR ν_{\max} 3304, 2937, 1649, 1531, 1456, 1384, 1361, 1290, 1220, 1176, 1045 cm⁻¹; ¹H and ¹³C NMR Data, Table S5; ESIMS *m/z* 764.9 [M + 2Na]²⁺, *m/z* 1506.8 [M + Na]⁺. HRESIMS *m/z* 764.9263 [M + 2Na]²⁺ (calcd for ½ C₇₀H₁₁₇N₁₇O₁₈Na₂, 764.9273, Δ 1.31 ppm).

Pentadecaibin V (5): white powder, $[\alpha]^{20}_D - 10.2$ (*c* 0.28, MeOH); UV (MeOH) λ_{\max} (log ϵ) 204 nm (3.46) nm; IR ν_{\max} 3305, 2933, 1647, 1531, 1455, 1384, 1360, 1288, 1219, 1172, 1043 cm⁻¹;

1
2
3 1 ^1H and ^{13}C NMR Data, Table S6; ESIMS m/z 764.9 $[\text{M} + 2\text{Na}]^{2+}$, m/z 1506.8 $[\text{M} + \text{Na}]^+$. HRESIMS
4
5 2 m/z 764.9249 $[\text{M} + 2\text{Na}]^{2+}$ (calcd for $\frac{1}{2} \text{C}_{70}\text{H}_{117}\text{N}_{17}\text{O}_{18}\text{Na}_2$, 764.9273, Δ 3.14 ppm).
6
7

8
9 3 **Marfey's Derivatization.** Compounds **1–5** (0.5 mg) and 500 μL of 6 M HCl were heated for
10
11 4 24 h at 110 $^\circ\text{C}$ in 4 mL sealed tubes (Supelco Analytical; Sigma-Aldrich). Hydrolyzed solutions of
12
13 5 peptaibols were evaporated to dryness under a stream of nitrogen and solubilized with 100 μL of
14
15 6 H_2O prior their derivatization with the FDAA Marfey's reagent (Thermo Fisher Scientific). Ten
16
17 7 microliters of each aqueous solution of hydrolyzed peptaibol were transferred in insert for 1 mL
18
19 8 HPLC vial and completed by 4 μL of 1 M sodium bicarbonate and 20 μL of Marfey's reagent (1%
20
21 9 in acetone). The resulting mixture was sealed and then heated at 40 $^\circ\text{C}$ during 2 h. After cooling,
22
23 10 samples were neutralized with 4 μL of 1 M HCl and diluted 1:3 with MeOH. The same treatment
24
25 11 was performed for the Marfey's derivatization of standard AA (Gly, Aib, *D*- and *L*- standards of
26
27 12 Glu, Ala, Val, Iva, Leu and Pheol). Aliquots (10 μL) of hydrolyzed peptaibols and standard AA
28
29 13 were analyzed by HPLC-UV on a reversed-phase analytical column (Inertsil ODS-3 RP18, 250 \times
30
31 14 4.6 mm, 5 μm , Interchim). The elution was insured at a constant flow rate of 0.5 mL/min using
32
33 15 CH_3CN / 0.05% TFA in H_2O as mobile phase. The gradient started at 20% CH_3CN ramping up to
34
35 16 50% over 20 min and was then held for 15 min. Detection was performed at 430 nm. All data were
36
37 17 acquired by HP ChemStation for LC.
38
39
40
41
42
43

44 18 **Genome Sequencing and 15-Module NRPS-encoding Gene Analysis.** *Trichoderma* sp.
45
46 19 MMS1255 was cultivated in the dark at 25 $^\circ\text{C}$ on PDA medium (potato 4 g/L, dextrose 20 g/L, agar
47
48 20 15 g/L, Difco Laboratories). Spore suspensions were produced and concentrations were adjusted
49
50 21 to 10^7 to 10^8 spores/mL prior to storage at -80 $^\circ\text{C}$ until use. Genomic DNA was extracted from fresh
51
52 22 mycelium, following the CTAB method proposed by the Joint Genome Institute with an optional
53
54 23 step using Qiagen genome-tips.⁶⁵ Genome was sequenced with PacBio technology. Sequences
55
56
57
58
59
60

1 were quality checked with FastQC.⁶⁶ The genome was assembled using canu.⁶⁷ Secondary
2 metabolism associated genes (polyketide synthase -PKS-, non ribosomal peptide synthetase -
3 NRPS-, terpene synthase -TPS-, dimethylallyl tryptophan synthase -DMATS-) and genes
4 potentially involved in adaptation to the environment were searched in each species. Gene cluster
5 associated with secondary metabolites were searched with FungiSMASH.⁵¹

6 **Cytotoxicity Assays.** KB cells (human oral epidermoid carcinoma ATCC CCL 17, American
7 Type Culture Collection,) were cultivated in RPMI (Roswell Park Memorial Institute medium)
8 supplemented with 5% (v/v) fetal calf serum, 1% (v/v) glutamine 200 mM and 1% (v/v)
9 streptomycin (10 mg/mL) / penicillin (1000 U) (all Sigma-Aldrich,). Cells were cultivated in plastic
10 flasks (Falcon; Becton Dickinson Labware,) at 37 °C in a 5% CO₂ enriched atmosphere. After an
11 incubation period of 48 h, trypsinized cells were suspended as a 2 × 10⁵ cells/mL suspension and
12 50 µL were put in each well of 96-well microplates (Nunclon Delta Surface; Thermo Fisher
13 Scientific). After an incubation of 48h, 50 µL of peptaibol samples were added to the initial 50-µL
14 cell suspension. Peptaibol samples were tested in well as a final 5% (v/v) methanolic solution in
15 supplemented RPMI with concentrations ranging from 0.6 to 25 µg/mL. A final 5% (v/v)
16 methanolic solution in supplemented RPMI was used as solvent control. Synthetic alamethicin⁵⁵
17 was used as positive control. After 76 h of incubation, the cell viability was evaluated by the
18 colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-
19 Aldrich) bioassay.^{68,69}

20 **Antimicrobial Assays.** The *C. albicans* clinical isolate was obtained from the Angers University
21 Hospital (Angers, France), *E. coli* (CIP54.8T) and *S. aureus* (CIP53.156) strains are part of the
22 Pasteur Institute Collection. Precultures were inoculated with loop-fulls of cells from agar plates

1 and incubated 20 h at the appropriate temperature 30 °C (for *C. albicans*) or 37 °C (for bacterial
2 strains) on a rotator in 5 mL YDP medium (yeast dextrose peptone) (for *C. albicans*) or LB medium
3 (Lysogeny Broth) (for bacterial strains). Overnight precultures were then harvested by
4 centrifugation, washed in sterile H₂O and inoculated to an optical density (OD) 0.5 in fresh YPD
5 or LB media. The microplate wells were filled with calibrated suspensions and peptaibols to be
6 tested at the desired concentration (ranging from 1 to 100 μg/mL in 1% MeOH, 300 μL/well) and
7 microbial growth was automatically recorded at 600 nm using a multiplate spectrophotometer
8 (Spectrostar nano; BMG Labtech). The plates were subjected to permanent shaking at 200 rpm and
9 OD measurements were taken every 10 min during a 24 h period. For each condition, the area
10 under the growth curve representative of the lag phase and the maximal growth rate was calculated
11 as previously described.⁷⁰ A percentage of growth inhibition was calculated for each independent
12 experiment ($100 - ((AUC_{treated}/AUC_c) \times 100$ where $AUC_{treated}$ is the Area Under the growth
13 Curve after exposure to the selected peptaibol or antibiotic, and AUC_c is the area under the growth
14 curve of a untreated culture). All data presented herein was obtained from two independent
15 biological repetitions and each repetition included three technical replicates. Amphotericin B
16 (100% inhibition of *C. albicans* at 30 μg/mL in 1% MeOH) and gentamycin (100% inhibition of
17 *E. coli* and *S. aureus* at 40 μg/mL in 1% MeOH) were used as positive controls.

18 ASSOCIATED CONTENT

19 **Supporting Information.** The Supporting Information is available free of charge on the ACS
20 Publications website at DOI: Morphological, genomic and phylogenetic analyses of *Trichoderma*
21 sp. MMS1255, MS and MS² spectra, 1D and 2D NMR spectra, ECD data and HPLC-UV data for
22 Marfey's analysis of compounds **1–5**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1

1
2
3 1 AUTHOR INFORMATION
45
6 2 Corresponding Author
78
9 3 *Phone: +33 (0)2 53 48 41 96. E-mail: nicolas.ruiz@univ-nantes.fr. Fax: +33 (0)2 53 48 41 09.
1011
12 4 orcid.org/0000-0001-7330-4679
1314
15 5 ACKNOWLEDGEMENTS
1617 6 This work was supported by a Ph.D grant for A.I.V.B. from the French Ministry of Higher
18 7 Education and Research. The authors acknowledge the French Ministry of Agriculture and Food
19 8 for the research program *NABUCO* (Ecophyto 2 plan). The 600 MHz NMR spectrometer used in
20 9 this study was funded jointly by the Région Ile-de-France, the Museum national d'Histoire
21 10 naturelle (Paris, France) and by CNRS (France). Dr. A. Blond is gratefully acknowledged for
22 11 recording the NMR spectra. Authors also thank Dr. M. Chollet-Krueler (COrint, University of
23 12 Rennes) for specific rotation measurements, A. Tonnerre (IICIMed, University of Nantes) for IR
24 13 spectroscopy and Prof. F. Fleury (IMPACT platform, Biogenouest, University of Nantes) for ECD
25 14 experiments. Are gratefully acknowledged Dr. Y. Fichou (ESC Bretagne Brest) for the PacBio
26 15 sequencing, Dr. A. Lebreton and Dr. E. Corre (Roscoff Marine Station, Sorbonne Univeristy) for
27 16 their help in the genome assemble and Prof. N. Inguibert (CRIOBE, University of Perpignan Via
28 17 Domitia) for providing synthetic alamethicin F50/5.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 REFERENCES

- (1) Chugh, J. K.; Wallace, B. A. *Biochem. Soc. Trans.* **2001**, *29* (4), 565-570.
- (2) Degenkolb, T.; Berg, A.; Gams, W.; Schlegel, B.; Gräfe, U. *J. Pept. Sci.* **2003**, *9* (11-12), 666-678.
- (3) Degenkolb, T.; Brückner, H. *Chem. Biodivers.* **2008**, *5* (9), 1817-1843.
- (4) Degenkolb, T.; Kirschbaum, J.; Brückner, H. *Chem. Biodivers.* **2007**, *4* (6), 1052-1067.
- (5) Mukherjee, P. K.; Wiest, A.; Ruiz, N.; Keightley, A.; Moran-Diez, M. E.; McCluskey, K.; Pouchus, Y. F.; Kenerley, C. M. *J. Biol. Chem.* **2011**, *286*, 4544-4554.
- (6) Reiber, K.; Neuhof, T.; Ozegowski, J. H.; Von Döhren, H.; Schwecke, T. *J. Pept. Sci.* **2003**, *9*, 701-713.
- (7) Wiest, A.; Grzegorski, D.; Xu, B. W.; Goulard, C.; Rebuffat, S.; Ebbola, D. J.; Bodo, B.; Kenerley, C. *J. Biol. Chem.* **2002**, *277* (23), 20862-20868.
- (8) Neumann, N. K. N.; Stoppacher, N.; Zeilinger, S.; Degenkolb, T.; Brückner, H.; Schuhmacher, R. *Chem. Biodivers.* **2015**, *12* (5), 743-751.
- (9) Stoppacher, N.; Neumann, N. K. N.; Burgstaller, L.; Zeilinger, S.; Degenkolb, T.; Brückner, H.; Schuhmacher, R. *Chem. Biodivers.* **2013**, *10* (5), 734-743.
- (10) Duclouhier, H. *Chem. Biodivers.* **2007**, *4* (6), 1023-1026.
- (11) Shi, M.; Wang, H. N.; Xie, S. T.; Luo, Y.; Sun, C. Y.; Chen, X. L.; Zhang, Y. *Z. Mol. Cancer* **2010**, *9* (1), 26.
- (12) Oh, S. U.; Yun, B. S.; Lee, S. J.; Kim, J. H.; Yoo, I. D. *J. Antibiot.* **2002**, *55* (6), 557-564.
- (13) Su, H. N.; Chen, Z. H.; Song, X. Y.; Chen, X. L.; Shi, M.; Zhou, B. C.; Zhao, X.; Zhang, Y. *Z. PLoS ONE* **2012**, *7* (9), e45818.
- (14) Summers, M. Y.; Kong, F.; Feng, X.; Siegel, M. M.; Janso, J. E.; Graziani, E. I.; Carter, G. T. *J. Nat. Prod.* **2007**, *70* (3), 391-396.
- (15) Ayers, S.; Ehrmann, B. M.; Adcock, A. F.; Kroll, D. J.; Carcache de Blanco, E. J.; Shen, Q.; Swanson, S. M.; Falkinham, J. O.; Wani, M. C.; Mitchell, S. M.; Pearce, C. J.; Oberlies, N. H. *J. Pept. Sci.* **2012**, *18* (8), 500-510.
- (16) Pruksakorn, P.; Arai, M.; Kotoku, N.; Vilchère, C.; Baughn, A. D.; Moodley, P.; Jacobs Jr, W. R.; Kobayashi, M. *Bioorg. Med. Chem. Lett.* **2010**, *20* (12), 3658-3663.
- (17) Pruksakorn, P.; Arai, M.; Liu, L.; Moodley, P.; Jacobs, W. R., Jr.; Kobayashi, M. *Biol. Pharm. Bull.* **2011**, *34* (8), 1287-1290.
- (18) Touati, I.; Ruiz, N.; Druzhinina, I.; Atanasova, L.; Tabenne, O.; Elkahoui, S.; Benzekri, R.; Bouslama, L.; Pouchus, Y. F.; Liman, F. *World J. Microbiol. Biotechnol.* **2018**, *34* (98), 1-12.
- (19) Song, X. Y.; Shen, Q. T.; Xie, S. T.; Chen, X. L.; Sun, C. Y.; Zhang, Y. *Z. FEMS Microbiol. Lett.* **2006**, *260* (1), 119-125.
- (20) Luo, Y.; Zhang, D. D.; Dong, X. W.; Zhao, P. B.; Chen, L. L.; Song, X. Y.; Wang, X. J.; Chen, X. L.; Shi, M.; Zhang, Y. *Z. FEMS Microbiol. Lett.* **2010**, *313* (2), 120-126.
- (21) Kim, Y. H.; Yeo, W. H.; Kim, Y. S.; Chae, S. Y.; Kim, K. S. *J. Microbiol. Biotechnol.* **2000**, *10* (4), 522-528.
- (22) Yun, B. S.; Yoo, I. D.; Kim, Y. H.; Kim, Y. S.; Lee, S. J.; Kim, K. S.; Yeo, W. H. *Tetrahedron Lett.* **2000**, *41* (9), 1429-1431.
- (23) El Hajji, M.; Rebuffat, S.; Le Doan, T.; Klein, G.; Satre, M.; Bodo, B. *Biochim. Biophys. Acta* **1989**, *978* (1), 97-104.

- 1
2
3 1 (24) Nagaraj, G.; Uma, M. V.; Shivayogi, M. S.; Balaram, H. *Antimicrob. Agents Chemother.*
4 2 **2001**, *45* (1), 145-149.
5 3 (25) Otto, A.; Laub, A.; Wendt, L.; Porzel, A.; Schmidt, J.; Palfner, G.; Becerra, J.; Krüger, D.;
6 4 Stadler, M.; Wessjohann, L.; Westermann, B.; Arnold, N. *J. Nat. Prod.* **2016**, *79* (4), 929-938.
7 5 (26) Degenkolb, T.; Nielsen, K. F.; Dieckmann, R.; Branco-Rocha, F.; Chaverri, P.; Samuels,
8 6 G. J.; Thrane, U.; von Döhren, H.; Vilcinskas, A.; Brückner, H. *Chem. Biodivers.* **2015**, *12* (4),
9 7 662-684.
10 8 (27) Shi, M.; Chen, L. L.; Wang, X. W.; Zhang, T.; Zhao, P. B.; Song, X. Y.; Sun, C. Y.; Chen,
11 9 X. L.; Zhou, B. C.; Zhang, Y. Z. *Microbiology* **2012**, *158*, 166-175.
12 10 (28) Viterbo, A.; Wiest, A.; Brotman, Y.; Chet, I.; Kenerley, C. *Mol. Plant Pathol.* **2007**, *8* (6),
13 11 737-746.
14 12 (29) Béven, L.; Duval, D.; Rebuffat, S.; Riddell, F. G.; Bodo, B.; Wróblewski, H. *Biochim.*
15 13 *Biophys. Acta* **1998**, *1372* (1), 78-90.
16 14 (30) Mohamed-Benkada, M.; François Pouchus, Y.; Vérité, P.; Pagniez, F.; Caroff, N.; Ruiz, N.
17 15 *Chemistry & Biodiversity* **2016**, *13* (5), 521-530.
18 16 (31) Carroux, A.; Van Bohemen, A. I.; Roullier, C.; Robiou du Pont, T.; Vansteelandt, M.;
19 17 Bondon, A.; Zalouk-Vergnoux, A.; Pouchus, Y. F.; Ruiz, N. *Chem. Biodivers.* **2013**, *10* (5), 772-
20 18 786.
21 19 (32) Ruiz, N.; Wielgosz-Collin, G.; Poirier, L.; Grovel, O.; Petit, K. E.; Mohamed-Benkada, M.;
22 20 Robiou du Pont, T.; Bissett, J.; Vérité, P.; Barnathan, G.; Pouchus, Y. F. *Peptides* **2007**, *28* (7),
23 21 1351-1358.
24 22 (33) Landreau, A.; Pouchus, Y. F.; Sallenave-Namont, C.; Biard, J. F.; Boumard, M. C.; Robiou
25 23 du Pont, T.; Mondeguer, F.; Goulard, C.; Verbist, J. F. *J. Microbiol. Meth.* **2002**, *48* (2-3), 181-
26 24 194.
27 25 (34) Chaverri, P.; Branco-Rocha, F.; Jaklitsch, W. M.; Gazis, R. O.; Degenkolb, T.; Samuels,
28 26 G. J. *Mycologia* **2015**, *107* (3), 558-590.
29 27 (35) Jaklitsch, W. M.; Voglmayr, H. *Mycotaxon* **2014**, *126* (1), 143-156.
30 28 (36) Druzhinina, I. S.; Kubicek, C. P.; Komoń-Zelazowska, M.; Mulaw, T. B.; Bissett, J. *BMC*
31 29 *Evol. Biol.* **2010**, *10* (1), 94.
32 30 (37) Taylor, J. W.; Jacobson, D. J.; Kroken, S.; Kasuga, T.; Geiser, D. M.; Hibbett, D. S.; Fisher,
33 31 M. C. *Fungal Genet. Biol.* **2000**, *31* (1), 21-32.
34 32 (38) Kumar, S.; Stecher, G.; Tamura, K. *Mol. Biol. Evol.* **2016**, *33* (7), 1870-1874.
35 33 (39) Hosotani, N.; Kumagai, K.; Honda, S.; Ito, A.; Shimatani, T.; Saji, I. *J. Antibiot.* **2007**, *60*
36 34 (3), 184-190.
37 35 (40) Rebuffat, S.; Goulard, C.; Bodo, B. *J. Chem. Soc. Perkin Trans. I* **1995**, 1849-1855.
38 36 (41) Toniolo, C.; Polese, A.; Formaggio, F.; Crisma, M.; Kamphuis, J. *J. Am. Chem. Soc.* **1996**,
39 37 *118* (11), 2744-2745.
40 38 (42) De Zotti, M.; Schievano, E.; Mammi, S.; Kaptein, B.; Broxterman, Q. B.; Singh, S. B.;
41 39 Brückner, H.; Toniolo, C. *Chem. Biodivers.* **2010**, *7* (6), 1612-1624.
42 40 (43) De Zotti, M.; Biondi, B.; Crisma, M.; Hjørringgaard, C. U.; Berg, A.; Brückner, H.;
43 41 Toniolo, C. *Pept. Sci.* **2011**, *98* (1), 36-49.
44 42 (44) Bhushan, R.; Brückner, H. *Amino Acids* **2004**, *27* (3), 231-247.
45 43 (45) Ritzau, M.; Heinze, S.; Dornberger, K.; Berg, A.; Fleck, W.; Schlegel, B.; Härtl, A.; Gräffe,
46 44 U. *J. Antibiot.* **1997**, *50* (9), 722-728.
47 45 (46) Lee, S. J.; Yun, B. S.; Cho, D. H.; Yoo, I. D. *J. Antibiot.* **1999**, *52* (11), 998-1006.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 (47) Kronen, M.; Kleinwachter, P.; Schlegel, B.; Hartl, A.; Grafe, U. *J. Antibiot.* **2001**, *54* (2),
2 175-178.
- 3 (48) Neuhof, T.; Berg, A.; Besl, H.; Schwecke, T.; Dieckmann, R.; von Dohren, H. *Chem.*
4 *Biodivers.* **2007**, *4* (6), 1103-1115.
- 5 (49) Berek, I.; Becker, A.; Schröder, H.; Härtl, A.; Höllt, V.; Grecksch, G. *Behav. Brain Res.*
6 **2009**, *203* (2), 232-239.
- 7 (50) Grigoriev, I. V.; Nikitin, R.; Haridas, S.; Kuo, A.; Ohm, R.; Otilar, R.; Riley, R.; Salamov,
8 A.; Zhao, X.; Korzeniewski, F.; Smirnova, T.; Nordberg, H.; Dubchak, I.; Shabalov, I. *Nucleic*
9 *Acids Res.* **2014**, *42* (D1), D699-D704.
- 10 (51) Blin, K.; Shaw, S.; Steinke, K.; Villebro, R.; Ziemert, N.; Lee, S. Y.; Medema, M. H.;
11 Weber, T. *Nucleic Acids Res.* **2019**, *47* (W1), W81-W87.
- 12 (52) Manavalan, B.; Murugapiran, S. K.; Lee, G.; Choi, S. *BMC Structural Biology* **2020**, *10*
13 (1), 1.
- 14 (53) Rausch, C.; Weber, T.; Kohlbacher, O.; Wohlleben, W.; Huson, D. H. *Nucleic Acids Res.*
15 **2005**, *33* (18), 5799-5808.
- 16 (54) Röttig, M.; Medema, M. H.; Blin, K.; Weber, T.; Rausch, C.; Kohlbacher, O. *Nucleic Acids*
17 *Res.* **2011**, *39* (suppl_2), W362-W367.
- 18 (55) Ben Haj Salah, K.; Inguibert, N. *Org. Lett.* **2016**, *16* (6), 1783-1785.
- 19 (56) Das, S.; Ben Haj Salah, K.; Wenger, E.; Martinez, J.; Kotarba, J.; Andreu, V.; Ruiz, N.;
20 Savini, F.; Stella, L.; Didierjean, C.; Legrand, B.; Inguibert, N. *Chem. Eur. J.* **2017**, *23* (71),
21 17964-17972.
- 22 (57) Jiao, W. H.; Khalil, Z.; Dewapriya, P.; Salim, A. A.; Lin, H. W.; Capon, R. J. *J. Nat. Prod.*
23 **2018**, *81* (4), 976-984.
- 24 (58) Goodwin, D. C.; Lee, S. B. *Biotechniques* **1993**, *15* (3), 438, 441-432, 444.
- 25 (59) Carbone, I.; Kohn, L. M. *Mycologia* **1999**, *91* (3), 553-556.
- 26 (60) White, T. J.; Bruns, T. D.; Lee, S.; Taylor, J., In *PCR protocols: a guide to methods and*
27 *applications*, Innis, M. A.; Gelfand, D. H.; Sninsky, J. J.; White, T. J., Eds. Academic Press:
28 London, 1990; pp 315-322.
- 29 (61) Liu, Y. J.; Whelen, S.; Hall, B. D. *Mol. Biol. Evol.* **1999**, *16* (12), 1799-1808.
- 30 (62) Jaklitsch, W. M.; Komon, M.; Kubicek, C. P.; Druzhinina, I. S. *Mycologia* **2005**, *97* (6),
31 1365-1378.
- 32 (63) Hall, T. A. *Nucleic Acids Symp. Ser.* **1999**, *41*, 95-98.
- 33 (64) Rodríguez, F.; Oliver, J. L.; Marín, A.; Medina, J. R. *J. Theor. Biol.* **1990**, *142* (4), 485-
34 501.
- 35 (65) Kohler, A.; Murat, C.; Costa, M. High quality genomic DNA extraction using CTAB and
36 qiagen genomic-tip. Version 2. INRA Nancy Equipe Ecogénomique UMR Iam, 2011.
37 [http://1000.fungalgenomes.org/home/wp-content/uploads/2013/02/genomicDNAProtocol-](http://1000.fungalgenomes.org/home/wp-content/uploads/2013/02/genomicDNAProtocol-AK0511.pdf)
38 [AK0511.pdf](http://1000.fungalgenomes.org/home/wp-content/uploads/2013/02/genomicDNAProtocol-AK0511.pdf) (accessed April 15, 2020).
- 39 (66) Andrews, S. FastQC: A quality control tool for high throughput sequence data, 2010.
40 <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (accessed April 15, 2020).
- 41 (67) Koren, S.; Walenz, B. P.; Berlin, K.; Miller, J. R.; Bergman, N. H.; Phillippy, A. M.
42 *Genome Research* **2017**, *27* (5), 722-736.
- 43 (68) Denizot, F.; Lang, R. *J. Immunol. Methods* **1986**, *89* (2), 271-277.
- 44 (69) Mosman, N. T. *J. Immunol. Methods* **1983**, *65*, 55-63.
- 45 (70) Gaucher, M.; Dugé de Bernonville, T.; Lohou, D.; Guyot, S.; Guillemette, T.; Brisset, M.
46 N.; Dat, J. F. *Phytochemistry* **2013**, *90*, 78-89.

